Actual and predicted survival time of patients with spinal metastases of lung cancer: Evaluation of the robustness of the tokuhashi score

Spine

Volumn 36, Issue 12, 2011, Pages 983-989

  Hessler, Christian ^a   Vettorazzi, Eik ^a   Madert, Juergen ^b   Bokemeyer, Carsten ^a   Panse, Jens ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

lung cancer; surgery; survival time; Tokuhashi score

Indexed keywords

ANTINEOPLASTIC AGENT; HEPARIN;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ARTICLE; ATELECTASIS; BLEEDING; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CHEMORADIOTHERAPY; CLINICAL DECISION MAKING; CONSERVATIVE TREATMENT; CORPORECTOMY; DECUBITUS; DURA LESION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HISTOLOGY; HUMAN; LAMINECTOMY; LARGE CELL CARCINOMA; LIFESPAN; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MENINX DISORDER; MULTIMODALITY CANCER THERAPY; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PARALYTIC ILEUS; PEROPERATIVE COMPLICATION; PLEURA EFFUSION; PNEUMONIA; POSTOPERATIVE COMPLICATION; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; RETROSPECTIVE STUDY; SCORING SYSTEM; SPINDLE CELL CARCINOMA; SPINE METASTASIS; SPINE STABILIZATION; SPINE SURGERY; SPONDYLODESIS; SURVIVAL TIME; TOKUHASHI SCORE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VALIDITY; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPINAL NEOPLASMS; SURVIVAL RATE;

EID: 79957739926     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181e8f7f8     Document Type: Article

References (50)

1. WHO Cancer. World Health Organization Retrieved on 2007-06-25, 2006
2. WHO Deaths by cause, sex and mortality stratum. World Health Organization Retrieved on 2008-12-25, 2004.
3. National Cancer Institute: Surveillance Epidemiology and end re-sults. Available at: http://seer.cancer.gov/statfacts/html/lungb.html. Accessed March 2008.
4. Fornasier VL, Horne JG. Metastases to the vertebral column. Cancer 1975;36(2): 590-4.
5. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma; analy-sis of 1000 autopsied cases. Cancer 1950; 3 (1): 74-85.
6. Sze WM, Shelley MD, Held I, et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy\a systemic review of randomised trials. Clin Oncol (R Coll Radiol) 2003; 15 (6): 345-52. (Pubitemid 37069647)
7. Singh K, Samartzis D, Vaccaro AR, et al. Current concepts in the management of metastatic spinal disease. The role of minimally-invasive approaches. J Bone Joint Surg Br 2006; 88 (4): 434-42.
8. Kocialkowski A, Webb JK. Metastatic spinal tumors: survival after surgery. Eur Spine J 1992; 1: 43-8.
9. Jónsson B, Jónsson H Jr., Karlström G, et al. Surgery of cervical spine metastases: a retrospective study. Eur Spine J 1994; 3: 76-83. (Pubitemid 24099158)
10. Riegel T, Schilling T, Sitter H, et al. Analysis of factors affecting the prognosis of vertebral metastases. Zentralbl Neurochir 2002; 63 (19): 2-6. (Pubitemid 34594875)
11. Hosono N, Ueda T, Tamura D, et al. Prognostic relevance of clini-cal symptoms in patients with spinal metastases. Clin Orthop Relat Res 2005; 436: 196-201. (Pubitemid 40961048)
12. Jansson KA, Bauer HCF. Survival, complications and outcome in 282 patients operated for neurological deficit due to thoracic or lumbal spinal metastases. Eur Spine J 2006; 15: 196-202.
13. Schaser KD, Melcher I, Mittlmeier T, et al. Surgical management of vertebral column metastatic disease. Unfallchirurg 2007; 110 (2): 137-59.
14. Tokuhashi Y, Yasumitsu A, Umezawa N. Outcome of treatment for spinal metastases using scoring system for preoperative evaluation of prognosis. Spine 2009; 34: 69-73.
15. Tokuhashi Y, Matsuzaki H, Toriyama S, et al. Scoring system for the preoperative evaluation of metastatic spine tumors prognosis. Spine 1990; 15: 1110-13.
16. Tokuhashi Y, Matsuzaki H, Oda H, et al. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine 2005; 19: 2186-91. (Pubitemid 41429199)
17. Enkaoua EA, Doursounian L, Chatellier G, et al. Vertebral metas-tases. A critical appreciation of the prognostic Tokuhashi-Score in a Series of 71 cases. Spine 1997; 25: 2293-8. (Pubitemid 28074061)
18. Tang V, Harvey D, Park Dorsay J, et al. Prognostic indicators in metastatic spinal cord compression: using functional independence measure and Tokuhashi scale to optimize rehabilitation planning. Spinal Cord 2007; 45 (10): 671-7. (Pubitemid 47530648)
19. Ulmar B, Huch K, Naumann U, et al. Evaluation of the Tokuhashi prognosis score and its modifications in 217 patients with vertebral metastases. Eur J Surg Oncol 2007; 33 (7): 914-19. (Pubitemid 47279046)
20. Putz C, Wiedenhöfer B, Gerner HJ, et al. Tokuhashi prognosis score: an important tool in prediction of the neurological outcome in metastatic spinal cord compression: a retrospective clinical study Spine 2008; 33 (24): 2669-74.
21. Yamashita T, Aota Y, Kushida K, et al. Changes in physical func-tion after palliative surgery for metastatic spinal tumor. Spine 2008; 33: 2341-6.
22. Bauer HC, Wedin R. Survival after surgery for spinal and extrem-ity metastases: prognostication in 241 patients. Acta Orthop Scand 1995; 66: 143-6.
23. Buchelt M, Windhager R, Kiss H, et al. Surgical treatment of spinal metastases. Z Orthop Ihre Grenzgeb 1996; 134 (3): 263-8.
24. Onimus M, Papin P, Gangloff S. Results of surgical treatment of spinal thoracic and lumbar metastases. Eur spine J 1996; 5 (6): 407-11. (Pubitemid 26422783)
25. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National cancer institute of canada clinical trials group. erlotinib in previously treated non-small-cell cancer. N Engl J Med 2005; 353 (2): 123-32. (Pubitemid 41058344)
26. Rompe J, Hopf CG, Eysel P. Outcome after palliative posterior sur-gery for metastatic disease of the spine-evaluation of 106 consecu-tive patients after decompression and stabilisation with the Cotrel-Dubousset instrumentation. Arch Orthop Trauma Surg 1999; 119: 394-400.
27. Weigel B, Maghsudi M, Neumann C, et al. Surgical management of symptomatic spinal metastases. Spine 1999; 24: 2240-6.
28. Wise JJ, Fischgrund JS, Herkowitz HN, et al. Complication, sur-vival rates and risk factors of surgery for metastatic disease of the spine. Spine 1999; 24: 1943-51. (Pubitemid 29449314)
29. Chataigner H, Onimus M. Surgery in spinal metastasis without spi-nal cord compression: indications and strategy related to the risk of recurrence. Eur Spine J 2000; 9: 523-7. (Pubitemid 32005656)
30. Ulmar B, Huch K, Kocak T, et al. The prognostic influence of pri-mary tumour and region of the affected spinal segment in 217 surgical patients with spinal metastases of different entities. Z Orthop 2007; 145: 31-8. (Pubitemid 46731607)
31. Walker MP, Yaszemski MJ, Kim CW, et al. Metastatic disease of the spine: evaluation and treatment. Clin Orthop Relat Res Oct 2003 (suppl 415): S165-75. (Pubitemid 37323334)
32. Ogihara S, Seichi A, Hozumi T, et al. Prognostic factors for patients with spinal metastases from lung cancer. Spine 2006; 14: 1585-90.
33. van der Linden YM, Dijkstra SP, Vonk EJ, et al. Dutch bone metas-tasis study group. prediction of survival in patients with metastases in the spinal column. Cancer 2005; 103: 320-8. (Pubitemid 40129292)
34. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive sur-gical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005; 366 (9486): 643-8. (Pubitemid 41176016)
35. Coleman RE. Skeletal complications of malignancy. Cancer 1997; (15)80 (suppl 8): S1588-94.
36. Schilsky RL. Personalizing cancer care: American society of clini-cal oncology presidential address 2009. J Clin Oncol 2009; 27 (23): 3725-30.
37. Sioutos PJ, Arbit E, Meshulam CF, et al. Spinal metastases from sol-id tumors. Analysis of factors affecting survival. Cancer 1995; 76: 1453-9.
38. Finkelstein JA, Zaveri G, Wai E, et al. A population-based study of surgery for spinal metastases. Survival rates and complications. J Bone Joint Surg Br 2003;85(7): 1045-50. (Pubitemid 37160693)
39. Huch K, Cakir B, Ulmar B, et al. Prognosis, surgical therapy and progression in cervical and upper-thoracic tumor osteolysis. Orthop Ihre Grenzgeb 2005; 143 (2): 213-18. (Pubitemid 40812828)
40. Ulmar B, Richter M, Cakir B, et al. The tokuhashi-score: significant predictive value for the life expectancy of patients with breast can-cer with spinal metastases. Spine 2005; 19: 2222-6. (Pubitemid 41429205)
41. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355 (24): 2542-50. (Pubitemid 44917502)
42. Horn L, Sandler A. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res 2009; 15 (16): 5040-8.
43. Wacker B, Nagrani T, Weinberg J, et al. Correlation between de-velopment of rash and efficacy in patients treated with the epider-mal growth factor receptor tyrosine inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13 (13): 3913-21. (Pubitemid 47037599)
44. Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008; 19 (2): 362-9. (Pubitemid 351201721)
45. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study com-paring cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26 (21): 3543-51.
46. Gandhi S, Walsh GL, Komaki R, et al. A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion. Ann Thorac Surg. 1999; 68 (5): 1778-84.
47. Barnes JB, Johnson SB, Dahiya RS, et al. Concomtant weekly cis-platin and thoracic radiotherapy for Pancoast tumors of the lung: pilot experience of the San Antonio Cancer Institute. Am J Clin Oncol 2002; 25 (1): 90-2. (Pubitemid 34131037)
48. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly pa-tients with advanced non-small-cell cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95 (5): 362-72. (Pubitemid 36395256)
49. Noda K, Nishiwaki Y, Kawahara M, et al. Japan Clinical Oncol-ogy Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell-lung cancer. N Engl J Med 2002; 346 (2): 85-91. (Pubitemid 34438898)
50. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial com-paring supportive care alone with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24: 5441-7. (Pubitemid 46623178)